<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31023785</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-3125</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer research : MCR</Title>
          <ISOAbbreviation>Mol Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.</ArticleTitle>
        <Pagination>
          <StartPage>1417</StartPage>
          <EndPage>1428</EndPage>
          <MedlinePgn>1417-1428</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/1541-7786.MCR-19-0147</ELocationID>
        <Abstract>
          <AbstractText>Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas typically developing in the context of neurofibromatosis type 1 (NF-1). With the exception of surgical resection, these tumors are resistant to all current therapies, and unresectable, recurrent, or metastatic tumors are considered incurable. Preclinical studies have identified several novel candidate molecular targets for therapeutic intervention, but, to date, targeted therapies have proven ineffective. Recent studies have identified recurrent mutations in polycomb repressive complex 2 (PRC2) core components, embryonic ectoderm development protein (EED) and suppressor of zeste 12 homolog (SUZ12), in MPNST. These mutations result in global loss of the histone H3 lysine 27 trimethylation epigenetic mark, normally deposited by PRC2, and subsequent gain in acetylation at this residue. This altered chromatin state has been shown to promote MPNST malignancy; however, acetylation at this residue sensitizes MPNSTs to BRD4 and bromodomain and extra-terminal domain inhibition. Interestingly, the catalytic component of PRC2, enhancer of zeste homolog 2 (EZH2), is not mutated in MPNST, hinting that a noncanonical, PRC2-independent function of EZH2 may play a role in this cancer. This review examines the pathobiology of MPNST, the contribution of PRC2 subunits to this process, and the prospects for PRC2-related therapies for this cancer. IMPLICATIONS: Identification of mutations in the PRC2 components EED and SUZ12 in the majority of MPNSTs may imply noncanonical oncogenic activities of the intact component, EZH2, and provide new opportunities for therapeutic intervention.</AbstractText>
          <CopyrightInformation>©2019 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Korfhage</LastName>
            <ForeName>Justin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Institute of Gerontology, University of Michigan, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lombard</LastName>
            <ForeName>David B</ForeName>
            <Initials>DB</Initials>
            <Identifier Source="ORCID">0000-0002-4292-0185</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Institute of Gerontology, University of Michigan, Ann Arbor, Michigan. davidlom@med.umich.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 GM101171</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL114858</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>04</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Cancer Res</MedlineTA>
        <NlmUniqueID>101150042</NlmUniqueID>
        <ISSNLinking>1541-7786</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C441289">BRD4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C491488">EED protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C430461">SUZ12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.43</RegistryNumber>
          <NameOfSubstance UI="C498409">EZH2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.43</RegistryNumber>
          <NameOfSubstance UI="D000071221">Enhancer of Zeste Homolog 2 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.43</RegistryNumber>
          <NameOfSubstance UI="D063151">Polycomb Repressive Complex 2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Mol Cancer Res. 2019 Oct;17(10):2139</RefSource>
          <PMID Version="1">31575727</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Mol Cancer Res. 2019 Oct;17(10):2140</RefSource>
          <PMID Version="1">31575728</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071221" MajorTopicYN="N">Enhancer of Zeste Homolog 2 Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081122" MajorTopicYN="N">Epigenome</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009456" MajorTopicYN="N">Neurofibromatosis 1</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="N">Neurofibrosarcoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063151" MajorTopicYN="N">Polycomb Repressive Complex 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflict of interest statement: D.B.L. has stock interest in ABBV, GILD, ILMN, INFI, JNJ, LCI, and TGTX. J.L.K. has no relevant financial interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31023785</ArticleId>
        <ArticleId IdType="mid">NIHMS1527582</ArticleId>
        <ArticleId IdType="pmc">PMC6610818</ArticleId>
        <ArticleId IdType="doi">10.1158/1541-7786.MCR-19-0147</ArticleId>
        <ArticleId IdType="pii">1541-7786.MCR-19-0147</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Uusitalo E, Leppävirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T, et al.
Incidence and Mortality of Neurofibromatosis: A Total Population Study in Finland. Journal of Investigative Dermatology
2015;135(3):904–6 doi 10.1038/jid.2014.465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2014.465</ArticleId>
            <ArticleId IdType="pubmed">25354145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Nyman JS, Ono K, Stevenson DA, Yang X, Elefteriou F. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Human molecular genetics
2011;20(20):3910–24 doi 10.1093/hmg/ddr310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddr310</ArticleId>
            <ArticleId IdType="pmc">PMC3177652</ArticleId>
            <ArticleId IdType="pubmed">21757497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevenson DA, Birch PH, Friedman JM, Viskochil DH, Balestrazzi P, Boni S, et al.
Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. American Journal of Medical Genetics
1999;84(5):413–9 doi 10.1002/(SICI)1096-8628(19990611)84:5&lt;413::AID-AJMG5&gt;3.0.CO;2-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1096-8628(19990611)84:5&lt;413::AID-AJMG5&gt;3.0.CO;2-1</ArticleId>
            <ArticleId IdType="pubmed">10360395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology
2005;65(7):1037 doi 10.1212/01.wnl.0000179303.72345.ce.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000179303.72345.ce</ArticleId>
            <ArticleId IdType="pubmed">16217056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, et al.
Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science
1990;249(4965):181 doi 10.1126/science.2134734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2134734</ArticleId>
            <ArticleId IdType="pubmed">2134734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proceedings of the National Academy of Sciences
1991;88(21):9658 doi 10.1073/pnas.88.21.9658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.88.21.9658</ArticleId>
            <ArticleId IdType="pmc">PMC52777</ArticleId>
            <ArticleId IdType="pubmed">1946382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cawthon RM, Weiss R, Xu G, Viskochil D, Culver M, Stevens J, et al.
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell
1990;62(1):193–201 doi 10.1016/0092-8674(90)90253-B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(90)90253-B</ArticleId>
            <ArticleId IdType="pubmed">2114220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin GA, Viskoohil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al.
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell
1990;63(4):843–9 doi 10.1016/0092-8674(90)90150-D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(90)90150-D</ArticleId>
            <ArticleId IdType="pubmed">2121370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu G, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, et al.
The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell
1990;63(4):835–41 doi 10.1016/0092-8674(90)90149-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(90)90149-9</ArticleId>
            <ArticleId IdType="pubmed">2121369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anastasaki C, Gutmann DH. Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation. Human Molecular Genetics
2014;23(25):6712–21 doi 10.1093/hmg/ddu389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddu389</ArticleId>
            <ArticleId IdType="pmc">PMC4245041</ArticleId>
            <ArticleId IdType="pubmed">25070947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong J, Hannan F, Zhu Y, Bernards A, Zhong Y. Neurofibromin regulates G protein–stimulated adenylyl cyclase activity. Nature Neuroscience
2002;5:95 doi 10.1038/nn792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn792</ArticleId>
            <ArticleId IdType="pubmed">11788835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo H-F, Tong J, Hannan F, Luo L, Zhong Y. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature
2000;403:895 doi 10.1038/35002593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35002593</ArticleId>
            <ArticleId IdType="pubmed">10706287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bollag G, McCormick F, Clark R. Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. The EMBO journal
1993;12(5):1923–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC413413</ArticleId>
            <ArticleId IdType="pubmed">8491185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, et al.
Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes &amp; Development
1994;8(9):1019–29 doi 10.1101/gad.8.9.1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.8.9.1019</ArticleId>
            <ArticleId IdType="pubmed">7926784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature Genetics
1994;7(3):353–61 doi 10.1038/ng0794-353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng0794-353</ArticleId>
            <ArticleId IdType="pubmed">7920653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knudson AG Jr., Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America
1971;68(4):820–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC389051</ArticleId>
            <ArticleId IdType="pubmed">5279523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Schepper S, Maertens O, Callens T, Naeyaert J-M, Lambert J, Messiaen L. Somatic Mutation Analysis in NF1 Café au lait Spots Reveals Two NF1 Hits in the Melanocytes. Journal of Investigative Dermatology
2008;128(4):1050–3 doi 10.1038/sj.jid.5701095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.jid.5701095</ArticleId>
            <ArticleId IdType="pubmed">17914445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell stem cell
2009;4(5):453–63 doi 10.1016/j.stem.2009.03.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2009.03.017</ArticleId>
            <ArticleId IdType="pmc">PMC2737469</ArticleId>
            <ArticleId IdType="pubmed">19427294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, Liu C, Patel AJ, Liao C-P, Wang Y, Le LQ. Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. Cancer cell
2014;26(5):695–706 doi 10.1016/j.ccell.2014.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2014.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC4254535</ArticleId>
            <ArticleId IdType="pubmed">25446898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, D’Astous JL, et al.
Double inactivation of NF1 in tibial pseudarthrosis. American journal of human genetics
2006;79(1):143–8 doi 10.1086/504441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/504441</ArticleId>
            <ArticleId IdType="pmc">PMC1474128</ArticleId>
            <ArticleId IdType="pubmed">16773574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riccardi VM, Lewis RA. Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants. American journal of human genetics
1988;42(2):284–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1715266</ArticleId>
            <ArticleId IdType="pubmed">3124613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huson SM, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. Journal of medical genetics
1989;26(11):704–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1015740</ArticleId>
            <ArticleId IdType="pubmed">2511318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riccardi VM. Neurofibromatosis: Clinical heterogeneity. Current Problems in Cancer
1982;7(2):1–34 doi 10.1016/S0147-0272(82)80016-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0147-0272(82)80016-0</ArticleId>
            <ArticleId IdType="pubmed">6816509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, et al.
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970–2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. American journal of human genetics
2007;80(1):140–51 doi 10.1086/510781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/510781</ArticleId>
            <ArticleId IdType="pmc">PMC1785321</ArticleId>
            <ArticleId IdType="pubmed">17160901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojnueangnit K, Xie J, Gomes A, Sharp A, Callens T, Chen Y, et al.
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Human mutation
2015;36(11):1052–63 doi 10.1002/humu.22832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.22832</ArticleId>
            <ArticleId IdType="pmc">PMC5049609</ArticleId>
            <ArticleId IdType="pubmed">26178382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, et al.
Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848. American journal of human genetics
2018;102(1):69–87 doi 10.1016/j.ajhg.2017.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajhg.2017.12.001</ArticleId>
            <ArticleId IdType="pmc">PMC5777934</ArticleId>
            <ArticleId IdType="pubmed">29290338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kayes LM, Burke W, Riccardi VM, Bennett R, Ehrlich P, Rubenstein A, et al.
Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. American journal of human genetics
1994;54(3):424–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1918114</ArticleId>
            <ArticleId IdType="pubmed">8116612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cnossen MH, van der Est MN, Breuning MH, van Asperen CJ, Breslau-Siderius EJ, van der Ploeg AT, et al.
Deletions spanning the neurofibromatosis type 1 gene: Implications for genotype-phenotype correlations in neurofibromatosis type 1?
Human Mutation
1997;9(5):458–64 doi 10.1002/(SICI)1098-1004(1997)9:5&lt;458::AID-HUMU13&gt;3.0.CO;2-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1098-1004(1997)9:5&lt;458::AID-HUMU13&gt;3.0.CO;2-1</ArticleId>
            <ArticleId IdType="pubmed">9143927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connell P, Viskochil D, Buchberg AM, Fountain J, Cawthon RM, Culver M, et al.
The human homolog of murine Evi-2 lies between two von Recklinghausen neurofibromatosis translocations. Genomics
1990;7(4):547–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2117565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viskochil D, Cawthon R, O’Connell P, Xu GF, Stevens J, Culver M, et al.
The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Molecular and cellular biology
1991;11(2):906–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC359746</ArticleId>
            <ArticleId IdType="pubmed">1899288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cawthon RM, Andersen LB, Buchberg AM, Xu GF, O’Connell P, Viskochil D, et al.
cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene. Genomics
1991;9(3):446–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1903357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandenbroucke I, Vandesompele J, De Paepe A, Messiaen L. Quantification of NF1 transcripts reveals novel highly expressed splice variants. FEBS Letters
2002;522(1–3):71–6 doi 10.1016/S0014-5793(02)02887-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(02)02887-9</ArticleId>
            <ArticleId IdType="pubmed">12095621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koliou X, Fedonidis C, Kalpachidou T, Mangoura D. Nuclear import mechanism of neurofibromin for localization on the spindle and function in chromosome congression. Journal of Neurochemistry
2016;136(1):78–91 doi 10.1111/jnc.13401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13401</ArticleId>
            <ArticleId IdType="pubmed">26490262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregory PE, Gutmann DH, Mitchell A, Park S, Boguski M, Jacks T, et al.
Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet
1993;19(3):265–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8332934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, Cheng Y, Gutmann DA, Mangoura D. Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. Developmental Brain Research
2001;130(2):231–48 doi 10.1016/S0165-3806(01)00190-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-3806(01)00190-0</ArticleId>
            <ArticleId IdType="pubmed">11675125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, et al.
The Neurofibromatosis Type 1 Gene Product Neurofibromin Enhances Cell Motility by Regulating Actin Filament Dynamics via the Rho-ROCK-LIMK2-Cofilin Pathway. Journal of Biological Chemistry
2005;280(47):39524–33 doi 10.1074/jbc.M503707200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M503707200</ArticleId>
            <ArticleId IdType="pubmed">16169856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang Y, Elahi A, Denley RC, Rao PH, Brennan MF, Jhanwar SC. Molecular Characterization of Permanent Cell Lines from Primary, Metastatic and Recurrent Malignant Peripheral Nerve Sheath Tumors (MPNST) with Underlying Neurofibromatosis-1. Anticancer Research
2009;29(4):1255–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19414372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krone W, Högemann I. Cell culture studies on neurofibromatosis (von Recklinghausen). Human Genetics
1986;74(4):453–5 doi 10.1007/BF00280506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00280506</ArticleId>
            <ArticleId IdType="pubmed">3098672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mechtersheimer G, Otaño-Joos M, Ohl S, Benner A, Lehnert T, Willeke F, et al.
Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes, Chromosomes and Cancer
1999;25(4):362–9 doi 10.1002/(SICI)1098-2264(199908)25:4&lt;362::AID-GCC8&gt;3.0.CO;2-Q.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1098-2264(199908)25:4&lt;362::AID-GCC8&gt;3.0.CO;2-Q</ArticleId>
            <ArticleId IdType="pubmed">10398430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plaat BEC, Molenaar WM, Mastik MF, Hoekstra HJ, te Meerman GJ, van den Berg E. Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: Sporadic Vs. neurofibromatosis-type-1-associated malignant schwannomas. International Journal of Cancer
1999;83(2):171–8 doi 10.1002/(SICI)1097-0215(19991008)83:2&lt;171::AID-IJC5&gt;3.0.CO;2-S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0215(19991008)83:2&lt;171::AID-IJC5&gt;3.0.CO;2-S</ArticleId>
            <ArticleId IdType="pubmed">10471523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt H, Taubert H, Würl P, Bache M, Bartel F, Holzhausen H-J, et al.
Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genetics and Cytogenetics
2001;128(1):14–23 doi 10.1016/S0165-4608(01)00393-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-4608(01)00393-4</ArticleId>
            <ArticleId IdType="pubmed">11454424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt H, Taubert H, Meye A, Würl P, Bache M, Bartel F, et al.
Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen’s disease. Cancer Letters
2000;155(2):181–90 doi 10.1016/S0304-3835(00)00426-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-3835(00)00426-2</ArticleId>
            <ArticleId IdType="pubmed">10822134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller RM, Sparkes RS. Segmental Neurofibromatosis. Archives of Dermatology
1977;113(6):837–8 doi 10.1001/archderm.1977.01640060133020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archderm.1977.01640060133020</ArticleId>
            <ArticleId IdType="pubmed">405930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paine RS. A clinical, pathological and genetic study of multiple neurofibromatosis. American Journal of Human Genetics
1956;8(3):190–1.</Citation>
        </Reference>
        <Reference>
          <Citation>Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H, et al.
Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. Journal of Clinical Oncology
2016;34(17):1978–86 doi 10.1200/JCO.2015.65.3576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.65.3576</ArticleId>
            <ArticleId IdType="pubmed">26926675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. British journal of cancer
2013;108(1):193–8 doi 10.1038/bjc.2012.535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2012.535</ArticleId>
            <ArticleId IdType="pmc">PMC3553528</ArticleId>
            <ArticleId IdType="pubmed">23257896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zöller MET, Rembeck B, Odén A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer
1997;79(11):2125–31 doi 10.1002/(SICI)1097-0142(19970601)79:11&lt;2125::AID-CNCR9&gt;3.0.CO;2-N.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0142(19970601)79:11&lt;2125::AID-CNCR9&gt;3.0.CO;2-N</ArticleId>
            <ArticleId IdType="pubmed">9179058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zinnamosca L, Petramala L, Cotesta D, Marinelli C, Schina M, Cianci R, et al.
Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Archives of Dermatological Research
2011;303(5):317–25 doi 10.1007/s00403-010-1090-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00403-010-1090-z</ArticleId>
            <ArticleId IdType="pubmed">21042801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. British journal of cancer
1994;70(5):969–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2033537</ArticleId>
            <ArticleId IdType="pubmed">7947106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, et al.
Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. Journal of medical genetics
2007;44(8):481–4 doi 10.1136/jmg.2007.049346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.2007.049346</ArticleId>
            <ArticleId IdType="pmc">PMC2597938</ArticleId>
            <ArticleId IdType="pubmed">17369502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlenterie M, Flucke U, Hofbauer LC, Timmers HJLM, Gastmeier J, Aust DE, et al.
Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. The American Journal of Medicine
2013;126(2):174–80 doi 10.1016/j.amjmed.2012.07.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjmed.2012.07.022</ArticleId>
            <ArticleId IdType="pubmed">23331445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. Journal of medical genetics
2002;39(5):311–4 doi 10.1136/jmg.39.5.311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.39.5.311</ArticleId>
            <ArticleId IdType="pmc">PMC1735122</ArticleId>
            <ArticleId IdType="pubmed">12011145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss SW, Goldblum JR. Enzinger and Weiss’ soft tissue tumors [electronic resource] /
Weiss Sharon W., Goldblum John R.
St. Louis Mo.; London:  :: Mosby Elsevier Science &amp; Technology; 2007.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al.
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. Journal of medical genetics
2007;44(2):81–8 doi 10.1136/jmg.2006.045906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.2006.045906</ArticleId>
            <ArticleId IdType="pmc">PMC2598063</ArticleId>
            <ArticleId IdType="pubmed">17105749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F-C, Chen S, Clegg T, Li X, Morgan T, Estwick SA, et al.
Nf1+/− mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Human molecular genetics
2006;15(16):2421–37 doi 10.1093/hmg/ddl165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddl165</ArticleId>
            <ArticleId IdType="pmc">PMC3024714</ArticleId>
            <ArticleId IdType="pubmed">16835260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F-C, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, et al.
Nf1-dependent tumors require a microenvironment containing Nf1+/−- and c-kit-dependent bone marrow. Cell
2008;135(3):437–48 doi 10.1016/j.cell.2008.08.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2008.08.041</ArticleId>
            <ArticleId IdType="pmc">PMC2788814</ArticleId>
            <ArticleId IdType="pubmed">18984156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F-C, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, et al.
Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/− mast cells. The Journal of clinical investigation
2003;112(12):1851–61 doi 10.1172/JCI19195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI19195</ArticleId>
            <ArticleId IdType="pmc">PMC296994</ArticleId>
            <ArticleId IdType="pubmed">14679180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan JJ, Klein KA, Neuberger TJ, Leftwich JA, Westin EH, Kauma S, et al.
Role for the stem cell factor/KIT complex in schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. Journal of Neuroscience Research
1994;37(3):415–32 doi 10.1002/jnr.490370314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.490370314</ArticleId>
            <ArticleId IdType="pubmed">7513766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, et al.
Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta neuropathologica
2013;125(1):159–68 doi 10.1007/s00401-012-1056-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-012-1056-7</ArticleId>
            <ArticleId IdType="pmc">PMC3547628</ArticleId>
            <ArticleId IdType="pubmed">23099891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaakkola S, Peltonen J, Riccardi V, Chu ML, Uitto J. Type 1 neurofibromatosis: selective expression of extracellular matrix genes by Schwann cells, perineurial cells, and fibroblasts in mixed cultures. The Journal of clinical investigation
1989;84(1):253–61 doi 10.1172/JCI114148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI114148</ArticleId>
            <ArticleId IdType="pmc">PMC303977</ArticleId>
            <ArticleId IdType="pubmed">2500456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cichowski K, Jacks T. NF1 Tumor Suppressor Gene Function: Narrowing the GAP. Cell
2001;104(4):593–604 doi 10.1016/S0092-8674(01)00245-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(01)00245-8</ArticleId>
            <ArticleId IdType="pubmed">11239415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson Y
MAST CELLS IN HUMAN PERIPHERAL NERVE. Acta Neurologica Scandinavica
1971;47(3):357–68 doi 10.1111/j.1600-0404.1971.tb07490.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.1971.tb07490.x</ArticleId>
            <ArticleId IdType="pubmed">4999559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi TA, Huang Y, Sidani A, Atit R, Largaespada DA, Boissy RE, et al.
A novel cytokine pathway suppresses glial cell melanogenesis after injury to adult nerve. The Journal of neuroscience : the official journal of the Society for Neuroscience
2002;22(22):9831–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1747535</ArticleId>
            <ArticleId IdType="pubmed">12427839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLaughlin ME, Jacks T. Progesterone Receptor Expression in Neurofibromas. Cancer Research
2003;63(4):752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12591720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fishbein L, Zhang X, Fisher LB, Li H, Campbell-Thompson M, Yachnis A, et al.
In vitro studies of steroid hormones in neurofibromatosis 1 tumors and schwann cells. Molecular Carcinogenesis
2007;46(7):512–23 doi 10.1002/mc.20236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.20236</ArticleId>
            <ArticleId IdType="pubmed">17393410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overdiek A, Winner U, Mayatepek E, Rosenbaum T. Schwann Cells From Human Neurofibromas Show Increased Proliferation Rates Under the Influence of Progesterone. Pediatric Research
2008;64:40 doi 10.1203/PDR.0b013e31817445b8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1203/PDR.0b013e31817445b8</ArticleId>
            <ArticleId IdType="pubmed">18360307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lammert M, Mautner V-F, Kluwe L. Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients. BMC Cancer
2005;5(1):16 doi 10.1186/1471-2407-5-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-5-16</ArticleId>
            <ArticleId IdType="pmc">PMC549555</ArticleId>
            <ArticleId IdType="pubmed">15703081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, Tsokos M, et al.
18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatric Blood &amp; Cancer
2013;60(1):59–64 doi 10.1002/pbc.24212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.24212</ArticleId>
            <ArticleId IdType="pmc">PMC6626667</ArticleId>
            <ArticleId IdType="pubmed">22645095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldwin A, Dombi E, Widemann BC, Higham CS, Bhaumik S, Rogiers A, et al.
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro-Oncology
2018;20(6):818–25 doi 10.1093/neuonc/noy013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noy013</ArticleId>
            <ArticleId IdType="pmc">PMC5961015</ArticleId>
            <ArticleId IdType="pubmed">29409029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beert E, Brems H, Daniëls B, De Wever I, Van Calenbergh F, Schoenaers J, et al.
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes, Chromosomes and Cancer
2011;50(12):1021–32 doi 10.1002/gcc.20921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.20921</ArticleId>
            <ArticleId IdType="pubmed">21987445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. The American journal of pathology
1999;155(6):1855–60 doi 10.1016/S0002-9440(10)65504-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)65504-6</ArticleId>
            <ArticleId IdType="pmc">PMC1866948</ArticleId>
            <ArticleId IdType="pubmed">10595915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Gutmann DH. International Consensus Statement on Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis 1. Cancer Research
2002;62(5):1573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11894862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradford D, Kim A. Current Treatment Options for Malignant Peripheral Nerve Sheath Tumors. Current Treatment Options in Oncology
2015;16(3):12 doi 10.1007/s11864-015-0328-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11864-015-0328-6</ArticleId>
            <ArticleId IdType="pubmed">25777573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernthal NM, Putnam A, Jones KB, Viskochil D, Randall RL. The effect of surgical margins on outcomes for low grade MPNSTs and atypical neurofibroma. Journal of Surgical Oncology
2014;110(7):813–6 doi 10.1002/jso.23736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.23736</ArticleId>
            <ArticleId IdType="pubmed">25111615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson KL, Al Sannaa GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, et al.
Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. Journal of neurosurgery
2017;126(1):319–29 doi 10.3171/2015.12.JNS152443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2015.12.JNS152443</ArticleId>
            <ArticleId IdType="pmc">PMC5045773</ArticleId>
            <ArticleId IdType="pubmed">27035165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolberg M, Høland M, Agesen TH, Brekke HR, Liestøl K, Hall KS, et al.
Survival meta-analyses for &gt;1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro-oncology
2013;15(2):135–47 doi 10.1093/neuonc/nos287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nos287</ArticleId>
            <ArticleId IdType="pmc">PMC3548581</ArticleId>
            <ArticleId IdType="pubmed">23161774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. The American journal of pathology
1999;155(6):1879–84 doi 10.1016/S0002-9440(10)65507-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)65507-1</ArticleId>
            <ArticleId IdType="pmc">PMC1866954</ArticleId>
            <ArticleId IdType="pubmed">10595918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahrmann EP, Moriarity BS, Otto GM, Watson AL, Choi K, Collins MH, et al.
Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. The American journal of pathology
2014;184(7):2082–98 doi 10.1016/j.ajpath.2014.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2014.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC4076465</ArticleId>
            <ArticleId IdType="pubmed">24832557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Scientific Reports
2017;7(1):14992 doi 10.1038/s41598-017-15183-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-15183-1</ArticleId>
            <ArticleId IdType="pmc">PMC5678116</ArticleId>
            <ArticleId IdType="pubmed">29118384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al.
Mouse Models of Tumor Development in Neurofibromatosis Type 1. Science
1999;286(5447):2172 doi 10.1126/science.286.5447.2172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.286.5447.2172</ArticleId>
            <ArticleId IdType="pubmed">10591652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type 1. Science (New York, NY)
1999;286(5447):2176–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3079436</ArticleId>
            <ArticleId IdType="pubmed">10591653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim M, et al.
The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer cell
2008;13(2):129–40 doi 10.1016/j.ccr.2008.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.01.003</ArticleId>
            <ArticleId IdType="pmc">PMC2566828</ArticleId>
            <ArticleId IdType="pubmed">18242513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodd RD, Mito JK, Eward WC, Chitalia R, Sachdeva M, Ma Y, et al.
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Molecular cancer therapeutics
2013;12(9):1906–17 doi 10.1158/1535-7163.MCT-13-0189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-0189</ArticleId>
            <ArticleId IdType="pmc">PMC3825462</ArticleId>
            <ArticleId IdType="pubmed">23858101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, et al.
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics
2014;46:1227 doi 10.1038/ng.309510.1038/ng.3095https://www.nature.com/articles/ng.3095#supplementary-informationhttps://www.nature.com/articles/ng.3095#supplementary-information .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3095</ArticleId>
            <ArticleId IdType="pmc">PMC4249650</ArticleId>
            <ArticleId IdType="pubmed">25240281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al.
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature
2014;514:247 doi 10.1038/nature13561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13561</ArticleId>
            <ArticleId IdType="pubmed">25119042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, et al.
Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nature Genetics
2014;46:1170 doi 10.1038/ng.3116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3116</ArticleId>
            <ArticleId IdType="pmc">PMC4383254</ArticleId>
            <ArticleId IdType="pubmed">25305755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohier P, Luscan A, Lloyd A, Ashelford K, Laurendeau I, Briand-Suleau A, et al.
Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. Genes, Chromosomes and Cancer
2017;56(5):421–6 doi 10.1002/gcc.22446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.22446</ArticleId>
            <ArticleId IdType="pubmed">28124441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proceedings of the National Academy of Sciences
2003;100(15):8758 doi 10.1073/pnas.1433065100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1433065100</ArticleId>
            <ArticleId IdType="pmc">PMC166386</ArticleId>
            <ArticleId IdType="pubmed">12840145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roe J-S, Mercan F, Rivera K, Pappin Darryl J, Vakoc Christopher R
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Molecular Cell
2015;58(6):1028–39 doi 10.1016/j.molcel.2015.04.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2015.04.011</ArticleId>
            <ArticleId IdType="pmc">PMC4475489</ArticleId>
            <ArticleId IdType="pubmed">25982114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Prakash C, Sum C, Gong Y, Li Y, Kwok JJT, et al.
Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. The Journal of biological chemistry
2012;287(51):43137–55 doi 10.1074/jbc.M112.413047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.413047</ArticleId>
            <ArticleId IdType="pmc">PMC3522308</ArticleId>
            <ArticleId IdType="pubmed">23086925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang MK, Mochizuki K, Zhou M, Jeong H-S, Brady JN, Ozato K. The Bromodomain Protein Brd4 Is a Positive Regulatory Component of P-TEFb and Stimulates RNA Polymerase II-Dependent Transcription. Molecular Cell
2005;19(4):523–34 doi 10.1016/j.molcel.2005.06.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2005.06.027</ArticleId>
            <ArticleId IdType="pubmed">16109376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al.
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing. Science
2002;298(5595):1039 doi 10.1126/science.1076997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1076997</ArticleId>
            <ArticleId IdType="pubmed">12351676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nature Reviews Genetics
2007;8:9 doi 10.1038/nrg1981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg1981</ArticleId>
            <ArticleId IdType="pubmed">17173055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong S, Cho Y-W, Yu L-R, Yu H, Veenstra TD, Ge K. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proceedings of the National Academy of Sciences of the United States of America
2007;104(47):18439–44 doi 10.1073/pnas.0707292104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0707292104</ArticleId>
            <ArticleId IdType="pmc">PMC2141795</ArticleId>
            <ArticleId IdType="pubmed">18003914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MG, Villa R, Trojer P, Norman J, Yan K-P, Reinberg D, et al.
Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination. Science
2007;318(5849):447 doi 10.1126/science.1149042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1149042</ArticleId>
            <ArticleId IdType="pubmed">17761849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agger K, Cloos PAC, Christensen J, Pasini D, Rose S, Rappsilber J, et al.
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature
2007;449:731 doi 10.1038/nature06145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature06145</ArticleId>
            <ArticleId IdType="pubmed">17713478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, Zlobin A, et al.
CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development (Cambridge, England)
2009;136(18):3131–41 doi 10.1242/dev.037127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.037127</ArticleId>
            <ArticleId IdType="pmc">PMC2730368</ArticleId>
            <ArticleId IdType="pubmed">19700617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds N, Salmon-Divon M, Dvinge H, Hynes-Allen A, Balasooriya G, Leaford D, et al.
NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression. The EMBO journal
2012;31(3):593–605 doi 10.1038/emboj.2011.431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emboj.2011.431</ArticleId>
            <ArticleId IdType="pmc">PMC3273378</ArticleId>
            <ArticleId IdType="pubmed">22139358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, et al.
Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic acids research
2010;38(15):4958–69 doi 10.1093/nar/gkq244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkq244</ArticleId>
            <ArticleId IdType="pmc">PMC2926606</ArticleId>
            <ArticleId IdType="pubmed">20385584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conway E, Healy E, Bracken AP. PRC2 mediated H3K27 methylations in cellular identity and cancer. Current Opinion in Cell Biology
2015;37:42–8 doi 10.1016/j.ceb.2015.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2015.10.003</ArticleId>
            <ArticleId IdType="pubmed">26497635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al.
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature
2002;419:624 doi 10.1038/nature01075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature01075</ArticleId>
            <ArticleId IdType="pubmed">12374981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al.
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America
2003;100(20):11606–11 doi 10.1073/pnas.1933744100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1933744100</ArticleId>
            <ArticleId IdType="pmc">PMC208805</ArticleId>
            <ArticleId IdType="pubmed">14500907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. The EMBO journal
2003;22(20):5323–35 doi 10.1093/emboj/cdg542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/cdg542</ArticleId>
            <ArticleId IdType="pmc">PMC213796</ArticleId>
            <ArticleId IdType="pubmed">14532106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al.
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature genetics
2010;42(2):181–5 doi 10.1038/ng.518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.518</ArticleId>
            <ArticleId IdType="pmc">PMC2850970</ArticleId>
            <ArticleId IdType="pubmed">20081860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al.
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America
2012;109(8):2989–94 doi 10.1073/pnas.1116418109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1116418109</ArticleId>
            <ArticleId IdType="pmc">PMC3287005</ArticleId>
            <ArticleId IdType="pubmed">22323599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majer CR, Jin L, Scott MP, Knutson SK, Kuntz KW, Keilhack H, et al.
A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Letters
2012;586(19):3448–51 doi 10.1016/j.febslet.2012.07.066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2012.07.066</ArticleId>
            <ArticleId IdType="pubmed">22850114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, et al.
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Molecular carcinogenesis
2008;47(9):701–6 doi 10.1002/mc.20413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.20413</ArticleId>
            <ArticleId IdType="pmc">PMC2580832</ArticleId>
            <ArticleId IdType="pubmed">18176935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, et al.
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nature medicine
2012;18(2):298–301 doi 10.1038/nm.2651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.2651</ArticleId>
            <ArticleId IdType="pmc">PMC3274628</ArticleId>
            <ArticleId IdType="pubmed">22237151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al.
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature
2012;481(7380):157–63 doi 10.1038/nature10725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10725</ArticleId>
            <ArticleId IdType="pmc">PMC3267575</ArticleId>
            <ArticleId IdType="pubmed">22237106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al.
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics
2010;42:722 doi 10.1038/ng.621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.621</ArticleId>
            <ArticleId IdType="pubmed">20601953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sashida G, Harada H, Matsui H, Oshima M, Yui M, Harada Y, et al.
Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nature Communications
2014;5:4177 doi 10.1038/ncomms5177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms5177</ArticleId>
            <ArticleId IdType="pubmed">24953053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al.
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (New York, NY)
2013;340(6134):857–61 doi 10.1126/science.1232245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1232245</ArticleId>
            <ArticleId IdType="pmc">PMC3951439</ArticleId>
            <ArticleId IdType="pubmed">23539183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones David TW, Konermann C, et al.
Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell
2012;22(4):425–37 doi 10.1016/j.ccr.2012.08.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2012.08.024</ArticleId>
            <ArticleId IdType="pubmed">23079654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al.
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature genetics
2012;44(3):251–3 doi 10.1038/ng.1102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.1102</ArticleId>
            <ArticleId IdType="pmc">PMC3288377</ArticleId>
            <ArticleId IdType="pubmed">22286216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E, Jacob K, et al.
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature
2012;482:226 doi 10.1038/nature10833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10833</ArticleId>
            <ArticleId IdType="pubmed">22286061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khuong-Quang D-A, Buczkowicz P, Rakopoulos P, Liu X-Y, Fontebasso AM, Bouffet E, et al.
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta neuropathologica
2012;124(3):439–47 doi 10.1007/s00401-012-0998-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-012-0998-0</ArticleId>
            <ArticleId IdType="pmc">PMC3422615</ArticleId>
            <ArticleId IdType="pubmed">22661320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, et al.
Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain pathology (Zurich, Switzerland)
2013;23(5):558–64 doi 10.1111/bpa.12042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bpa.12042</ArticleId>
            <ArticleId IdType="pmc">PMC3701028</ArticleId>
            <ArticleId IdType="pubmed">23414300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel AJ, Liao C-P, Chen Z, Liu C, Wang Y, Le LQ. BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell reports
2014;6(1):81–92 doi 10.1016/j.celrep.2013.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2013.12.001</ArticleId>
            <ArticleId IdType="pmc">PMC3904298</ArticleId>
            <ArticleId IdType="pubmed">24373973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, Garnett J, Creighton CJ, Al Sannaa GA, Igram DR, Lazar A, et al.
EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. The Journal of pathology
2014;232(3):308–18 doi 10.1002/path.4294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.4294</ArticleId>
            <ArticleId IdType="pmc">PMC4166508</ArticleId>
            <ArticleId IdType="pubmed">24132643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, Yang X, Ma X, Ingram DR, Lazar AJ, Torres KE, et al.
Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Molecular cancer
2015;14:55- doi 10.1186/s12943-015-0325-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-015-0325-1</ArticleId>
            <ArticleId IdType="pmc">PMC4357176</ArticleId>
            <ArticleId IdType="pubmed">25890085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao RC, Chan MP, Andrews CA, Kahana A. Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification? - a short report. Cellular Oncology
2018;41(6):693–8 doi 10.1007/s13402-018-0402-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13402-018-0402-8</ArticleId>
            <ArticleId IdType="pmc">PMC6536376</ArticleId>
            <ArticleId IdType="pubmed">30215205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao RC, Chan MP, Andrews CA, Kahana A. EZH2, Proliferation Rate, and Aggressive Tumor Subtypes in Cutaneous Basal Cell Carcinoma. JAMA oncology
2016;2(7):962–3 doi 10.1001/jamaoncol.2016.0021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.0021</ArticleId>
            <ArticleId IdType="pmc">PMC4945394</ArticleId>
            <ArticleId IdType="pubmed">27054919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, Howlin J, et al.
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Molecular oncology
2012;6(5):494–506 doi 10.1016/j.molonc.2012.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2012.06.002</ArticleId>
            <ArticleId IdType="pmc">PMC5528390</ArticleId>
            <ArticleId IdType="pubmed">22766277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, et al.
Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Molecular and cellular biology
2007;27(14):5105–19 doi 10.1128/MCB.00162-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00162-07</ArticleId>
            <ArticleId IdType="pmc">PMC1951944</ArticleId>
            <ArticleId IdType="pubmed">17502350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Shuet T, Li Z, Wu Z, Aau M, Guan P, Karuturi RKM, et al.
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers. Molecular Cell
2011;43(5):798–810 doi 10.1016/j.molcel.2011.08.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2011.08.011</ArticleId>
            <ArticleId IdType="pubmed">21884980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung H-Y, Jun S, Lee M, Kim H-C, Wang X, Ji H, et al.
PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation. Molecular cell
2013;52(2):193–205 doi 10.1016/j.molcel.2013.08.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2013.08.028</ArticleId>
            <ArticleId IdType="pmc">PMC4040269</ArticleId>
            <ArticleId IdType="pubmed">24055345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan J, Li B, Lin B, Lee PT, Chung T-H, Tan J, et al.
EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood
2016;128(7):948 doi 10.1182/blood-2016-01-690701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2016-01-690701</ArticleId>
            <ArticleId IdType="pubmed">27297789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anwar T, Arellano-Garcia C, Ropa J, Chen Y-C, Kim HS, Yoon E, et al.
p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. Nature Communications
2018;9(1):2801 doi 10.1038/s41467-018-05078-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-05078-8</ArticleId>
            <ArticleId IdType="pmc">PMC6051995</ArticleId>
            <ArticleId IdType="pubmed">30022044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Ih, Dobenecker M-W, Dickinson E, Oser M, Basavaraj A, Marqueron R, et al.
Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling. Cell
2005;121(3):425–36 doi 10.1016/j.cell.2005.02.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2005.02.029</ArticleId>
            <ArticleId IdType="pubmed">15882624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al.
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (New York, NY)
2012;338(6113):1465–9 doi 10.1126/science.1227604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1227604</ArticleId>
            <ArticleId IdType="pmc">PMC3625962</ArticleId>
            <ArticleId IdType="pubmed">23239736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim E, Kim M, Woo D-H, Shin Y, Shin J, Chang N, et al.
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer cell
2013;23(6):839–52 doi 10.1016/j.ccr.2013.04.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.04.008</ArticleId>
            <ArticleId IdType="pmc">PMC4109796</ArticleId>
            <ArticleId IdType="pubmed">23684459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cha T-L, Zhou BP, Xia W, Wu Y, Yang C-C, Chen C-T, et al.
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3. Science
2005;310(5746):306 doi 10.1126/science.1118947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1118947</ArticleId>
            <ArticleId IdType="pubmed">16224021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crim JR, Seeger LL, Yao L, Chandnani V, Eckardt JJ. Diagnosis of soft-tissue masses with MR imaging: can benign masses be differentiated from malignant ones?
Radiology
1992;185(2):581–6 doi 10.1148/radiology.185.2.1410377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiology.185.2.1410377</ArticleId>
            <ArticleId IdType="pubmed">1410377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine E, Huntrakoon M, Wetzel LH. Malignant nerve-sheath neoplasms in neurofibromatosis: distinction from benign tumors by using imaging techniques. American Journal of Roentgenology
1987;149(5):1059–64 doi 10.2214/ajr.149.5.1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/ajr.149.5.1059</ArticleId>
            <ArticleId IdType="pubmed">3118667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albritton KH, Rankin C, Coffin CM, Ratner N, Budd GT, Schuetze SM, et al.
Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). Journal of Clinical Oncology
2006;24(18_suppl):9518- doi 10.1200/jco.2006.24.18_suppl.9518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2006.24.18_suppl.9518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Hensley ML, Hirst CM, et al.
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. The Oncologist
2018.  doi 10.1634/theoncologist.2018-0160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0160</ArticleId>
            <ArticleId IdType="pmc">PMC6656505</ArticleId>
            <ArticleId IdType="pubmed">30126857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu LMN, Deng Y, Wang J, Zhao C, Wang J, Rao R, et al.
Programming of Schwann Cells by Lats½-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. Cancer Cell
2018;33(2):292–308.e7 doi 10.1016/j.ccell.2018.01.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.01.005</ArticleId>
            <ArticleId IdType="pmc">PMC5813693</ArticleId>
            <ArticleId IdType="pubmed">29438698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, et al.
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma
2017;2017:8685638- doi 10.1155/2017/8685638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/8685638</ArticleId>
            <ArticleId IdType="pmc">PMC5613633</ArticleId>
            <ArticleId IdType="pubmed">29138631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patwardhan PP, Surriga O, Beckman MJ, de Stanchina E, Dematteo RP, Tap WD, et al.
Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clinical cancer research : an official journal of the American Association for Cancer Research
2014;20(12):3146–58 doi 10.1158/1078-0432.CCR-13-2576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-2576</ArticleId>
            <ArticleId IdType="pmc">PMC4060793</ArticleId>
            <ArticleId IdType="pubmed">24718867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu Y-H, et al.
Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model. Molecular Therapy
2007;15(2):279–86 doi 10.1038/sj.mt.6300038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mt.6300038</ArticleId>
            <ArticleId IdType="pubmed">17235305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du X, Yang J, Ylipää A, Zhu Z. Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor. Journal of hematology &amp; oncology
2013;6:93- doi 10.1186/1756-8722-6-93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-8722-6-93</ArticleId>
            <ArticleId IdType="pmc">PMC3878771</ArticleId>
            <ArticleId IdType="pubmed">24341609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, et al.
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Molecular cancer therapeutics
2008;7(4):890–6 doi 10.1158/1535-7163.MCT-07-0518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-07-0518</ArticleId>
            <ArticleId IdType="pmc">PMC3267321</ArticleId>
            <ArticleId IdType="pubmed">18413802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proceedings of the National Academy of Sciences of the United States of America
2005;102(24):8573–8 doi 10.1073/pnas.0503224102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0503224102</ArticleId>
            <ArticleId IdType="pmc">PMC1142482</ArticleId>
            <ArticleId IdType="pubmed">15937108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou CY, Smith KD, Zhu Q-S, Liu J, McCutcheon IE, Slopis JM, et al.
Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Molecular Cancer Therapeutics
2009;8(5):1157 doi 10.1158/1535-7163.MCT-08-1008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-08-1008</ArticleId>
            <ArticleId IdType="pubmed">19417153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson G, Mahller YY, Collins MH, Kim M-O, Nobukuni T, Perentesis J, et al.
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Molecular cancer therapeutics
2008;7(5):1237–45 doi 10.1158/1535-7163.MCT-07-2335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-07-2335</ArticleId>
            <ArticleId IdType="pmc">PMC2855168</ArticleId>
            <ArticleId IdType="pubmed">18483311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, et al.
Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. International Journal of Cancer
2010;126(2):563–71 doi 10.1002/ijc.24783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.24783</ArticleId>
            <ArticleId IdType="pubmed">19634141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen CM, Johnson BW, Williams Sybil MG, Chan AW, Reczek EE, Lynch RC, et al.
TORC1 Is Essential for NF1-Associated Malignancies. Current Biology
2008;18(1):56–62 doi 10.1016/j.cub.2007.11.066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2007.11.066</ArticleId>
            <ArticleId IdType="pubmed">18164202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al.
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas. New England Journal of Medicine
2016;375(26):2550–60 doi 10.1056/NEJMoa1605943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1605943</ArticleId>
            <ArticleId IdType="pmc">PMC5508592</ArticleId>
            <ArticleId IdType="pubmed">28029918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shurell E, Singh AS, Crompton JG, Jensen S, Li Y, Dry S, et al.
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget
2016;7(39):64300–8 doi 10.18632/oncotarget.11734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.11734</ArticleId>
            <ArticleId IdType="pmc">PMC5325443</ArticleId>
            <ArticleId IdType="pubmed">27588404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science translational medicine
2016;8(328):328rv4–rv4 doi 10.1126/scitranslmed.aad7118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aad7118</ArticleId>
            <ArticleId IdType="pmc">PMC4859220</ArticleId>
            <ArticleId IdType="pubmed">26936508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, et al.
Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget
2017;8(47):82037–48 doi 10.18632/oncotarget.18301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.18301</ArticleId>
            <ArticleId IdType="pmc">PMC5669868</ArticleId>
            <ArticleId IdType="pubmed">29137242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. Sarcoma
2017;2017:7429697- doi 10.1155/2017/7429697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/7429697</ArticleId>
            <ArticleId IdType="pmc">PMC5448069</ArticleId>
            <ArticleId IdType="pubmed">28592921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo W, Chen J, Patel A, Zhang L, Chau V, Li Y, et al.
CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell
2013;152(5):1077–90 doi 10.1016/j.cell.2013.01.053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.01.053</ArticleId>
            <ArticleId IdType="pmc">PMC3594500</ArticleId>
            <ArticleId IdType="pubmed">23434321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chau V, Lim SK, Mo W, Liu C, Patel AJ, McKay RM, et al.
Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer research
2014;74(2):586–97 doi 10.1158/0008-5472.CAN-13-1934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1934</ArticleId>
            <ArticleId IdType="pmc">PMC3947005</ArticleId>
            <ArticleId IdType="pubmed">24285727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Chang L-J, Neubauer DR, Muir DF, Wallace MR. Immortalization of human normal and NF1 neurofibroma Schwann cells. Laboratory Investigation
2016;96:1105 doi 10.1038/labinvest.2016.88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.2016.88</ArticleId>
            <ArticleId IdType="pubmed">27617404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson KJ, Hussain I, Williams K, Santens R, Mueller NL, Gutmann DH. Development of an international internet-based neurofibromatosis Type 1 Patient registry. Contemporary Clinical Trials
2013;34(2):305–11 doi 10.1016/j.cct.2012.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cct.2012.12.002</ArticleId>
            <ArticleId IdType="pubmed">23246715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidlin M, Holzman R, Knight P, Korf B, Rangel Miller V, Viskochil D, et al.
Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study. PloS one
2017;12(6):e0178639-e doi 10.1371/journal.pone.0178639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0178639</ArticleId>
            <ArticleId IdType="pmc">PMC5482445</ArticleId>
            <ArticleId IdType="pubmed">28644838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, et al.
Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex. Cell
2002;111(2):197–208 doi 10.1016/S0092-8674(02)00976-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(02)00976-5</ArticleId>
            <ArticleId IdType="pubmed">12408864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ 3rd, et al.
Role of the polycomb protein EED in the propagation of repressive histone marks. Nature
2009;461(7265):762–7 doi 10.1038/nature08398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08398</ArticleId>
            <ArticleId IdType="pmc">PMC3772642</ArticleId>
            <ArticleId IdType="pubmed">19767730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, et al.
A model for transmission of the H3K27me3 epigenetic mark. Nature Cell Biology
2008;10:1291 doi 10.1038/ncb1787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1787</ArticleId>
            <ArticleId IdType="pubmed">18931660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao R, Zhang Y. SUZ12 Is Required for Both the Histone Methyltransferase Activity and the Silencing Function of the EED-EZH2
Complex. Molecular Cell
2004;15(1):57–67 doi 10.1016/j.molcel.2004.06.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2004.06.020</ArticleId>
            <ArticleId IdType="pubmed">15225548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davidovich C, Cech TR. The recruitment of chromatin modifiers by long noncoding RNAs: lessons from PRC2. RNA (New York, NY)
2015;21(12):2007–22 doi 10.1261/rna.053918.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1261/rna.053918.115</ArticleId>
            <ArticleId IdType="pmc">PMC4647455</ArticleId>
            <ArticleId IdType="pubmed">26574518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitges Frank W, Prusty Archana B, Faty M, Stützer A, Lingaraju Gondichatnahalli M, Aiwazian J, et al.
Histone Methylation by PRC2 Is Inhibited by Active Chromatin Marks. Molecular Cell
2011;42(3):330–41 doi 10.1016/j.molcel.2011.03.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2011.03.025</ArticleId>
            <ArticleId IdType="pubmed">21549310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayliss J, Mukherjee P, Lu C, Jain SU, Chung C, Martinez D, et al.
Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Science Translational Medicine
2016;8(366):366ra161 doi 10.1126/scitranslmed.aah6904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aah6904</ArticleId>
            <ArticleId IdType="pmc">PMC5123566</ArticleId>
            <ArticleId IdType="pubmed">27881822</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
